Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically modified dendritic cells for cancer immunotherapy.

Antoni Ribas1

  • 1Division of Hematology-Oncology, University of California at Los Angeles, CA 90095-1782, USA. aribas@mednet.ucla.edu

Current Gene Therapy
|February 7, 2006
PubMed
Summary

Genetically engineered dendritic cells (DCs) show promise for cancer immunotherapy by enhancing immune responses against tumors. While preclinical studies are encouraging, clinical trials indicate safe T cell activation but limited patient responses.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

882
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
882

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Cancer discovery·2026
Same author

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

Nature communications·2026
Same author

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.

Targeted oncology·2026

Area of Science:

  • Immunology
  • Oncology
  • Gene Therapy

Background:

  • Dendritic cells (DCs) are crucial for initiating immune responses against tumor antigens.
  • Ex vivo genetic modification of DCs enhances their immune-stimulating capabilities for cancer therapy.

Purpose of the Study:

  • To review methods for genetically modifying dendritic cells (DCs) for cancer immunotherapy.
  • To evaluate the efficacy and safety of engineered DCs in preclinical and clinical settings.

Main Methods:

  • Genetic engineering of DCs using physical methods (transfection, electroporation, gene guns) and viral vectors (adenovirus, retrovirus, lentivirus, poxvirus, AAV).
  • Engineering DCs for tumor antigen expression or enhanced immune stimulatory functions.
  • Analysis of preclinical models and clinical trial data.

Related Experiment Videos

Main Results:

  • Various methods, including viral vectors, enable efficient gene transfer into DCs.
  • Engineered DCs can induce T cell activation in preclinical and clinical studies.
  • Preliminary clinical trials show safety and T cell induction, but limited clinical responses.

Conclusions:

  • Genetically modified DCs hold potential for cancer immunotherapy.
  • Further optimization is needed to improve clinical efficacy and patient responses.